Table 1.

Human Immunodeficiency Virus–Infected Participants Who Received Systemic Chemotherapy for Malignancies, Underwent Longitudinal Sampling, and Were Included in the Analyses

Participant	Sex	Diagnosis	Chemotherapy Regimen	On ART During Chemotherapy or HSCT	Peak VL on Reservoir Study (HIV 1 RNA Copies/mL)	Timing of Baseline Sample (Days Prior to or Following First Chemotherapy Cycle)
1	F	DLBCL	R-EPOCH, R-CODOX-M/ IVAC	No	1630000	124
2	M	DLBCL	R-CHOP	Yes	539	–7
3	M	DLBCL	R-CHOP	Yes	134	152
4	M	DLBCL	R-CHOP	Yes	<50	0
5	M	DLBCL	R-EPOCH	Yes	<50	65
6	M	DLBCL	EPOCH, itMTX, DHAP	Yes	<50	12
7	M	NHL/Hodgkin	ABVD	Yes	<50	119
8	M	Hodgkin	ABVD	Yes	61	–1
9	M	KS	Doxorubicin, paclitaxel	Yes	269000a	0
10	M	KS	Doxorubicin	Yes	<50	3
11	M	MCD/KS	Rituximab	Yes	321	0
12	M	RCC	Carboplatin + gemcitabine	Yes	<50	131
13	M	RCC	Pazopanib, everolimus	Yes	<50	126 (pazopanib), –391 (everolimus)
14	M	Hodgkin	Autologous HSCT	Yes	246	–10 (pre-HSCT)
15	M	PTCL	Autologous HSCT	No	1660000b	–120 (pre-HSCT)

Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ART, antiretroviral therapy; DHAP, dexamethasone, cytarabine, cisplatin; DLBCL, diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; HSCT, hematopoietic stem cell transplantation; itMTX, intrathecal methotrexate; KS, Kaposi sarcoma; MCD, multicentric Castleman disease; NHL, non-Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma; RCC, renal cell carcinoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CODOX-M/IVAC, rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, cytarabine; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; VL, viral load.

^aParticipant started ART at first chemotherapy infusion, VL decreased to 32 copies/mL during subsequent chemotherapy cycles.

^bParticipant discontinued ART at the time of autologous HSCT (pretransplant VL = 22 copies/mL).